Clinical Observations of 121 Nasopharyngeal Carcinoma Patients Treated with Helical Tomotherapy
L. Ma,L. Du,L. Feng,G. Zhou,B. Qu,G. Ren,S. Xu,C. Xie,X. Zhang,F. Li
DOI: https://doi.org/10.1016/j.ijrobp.2011.06.1048
2011-01-01
Abstract:To report 3 years clinical outcome of 121 nasopharyngeal carcinoma (NPC) patients treated with Tomotherapy in China. Between September 2007 and August 2010, 93 male and 28 female (total 121) newly diagnosed NPC patients were treated with TomoTherapy with IMRT/IGRT protocols. Median age was 42 (11 - 82), with 3 squamous and 118 non-keratinizing carcinomas. Distributions of clinical stages were: 11, 43, 43, 24 for Stage I, II, II, IVa according to Fouzhou 92's Staging and 8, 49, 40, 24 for Stage I, II, II, IVa-b according to UICC 2002 Staging. Patients were immobilized in a commercial thermoplastic cast from head to shoulders, and 3 mm thickness diagnostic CT scan slices of the head and neck protocol were acquired for targets and OARs contouring. Prescription dose was designed as 70 - 74 Gy in 33 fractions to gross tumor volume and positive lymph nodes, with 60 - 62.7 Gy in 33 fractions to high risk planning target volume, while delivering 52 - 56Gy in 33 fractions to low risk planning target volume. Thirty-one patients were treated with radiation therapy as a single modality, 35 with concurrent chemo-radiotherapy, 36 with EGFR monoclonal antibody (Cetuximab or Nimotuzumab), and 19 combined with chemotherapy and EGFR monoclonal antibody. Preliminary tumor response was observed and analyzed. Acute side-effects and late xerostomia were evaluated with the established RTOG/EORTC criteria. Local relapse-free survival (LRFS), nodal relapse-free survival (NRFS), distant metastasis-free survival (DMFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Average beam-on-time for NPC treatment was 457.6 sec/Fx (358.0- 696.1 sec). The median follow-up was 21 (6 - 42) months. Acute side-effects were evaluated, skin toxicities of Grade 0, 1, 2 and 3 were 5.0%, 74.4%, 15.7% and 4.9%; mucositis of Grade 0, 1, 2 and 3 were 0.8%, 37.2%, 57.9% and 4.1%; xerostomia of grade 0, 1, 2 and 3 were 3.3%, 53.7%, 43.0% and 0; respectively. Concurrent chemotherapy significantly increased the incidence of severe acute toxicities. The remission rates (CR+PR) noted 1 month after radiation therapy for primary tumor and positive lymph nodes were 95.0% and 99.0%. Parotid gland functions restored with time during study period, no grade 2 or more xerostomia was noted 12 months after radiation therapy. The LRFS, NRFS, DMFS and OS were 96.4%, 100%, 97.3% and 96.5% for one year; 94.6%, 100%, 93.2% and 92.6% for two years; 94.6%, 100%, 87.4 and 86.8% for three years, respectively. Incidence of severe acute toxicities and late xerostomia is relatively minor for NPC patients treated with helical tomotherapy which presents great advantages from both planning and delivery aspects for local control and reduction of side effects. Long-term clinical outcome for these patients is under investigation.